# Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study.

- **DOI:** [10.3389/fimmu.2026.1750735](https://doi.org/10.3389/fimmu.2026.1750735)
- **Rating:** Sound (3.5 out of 5)
- **Verdict:** Prospective Chinese data corroborate lanadelumab’s established profile, but the selected uncontrolled cohort limits independent efficacy inference.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-09-18
- **Evaluation page:** https://www.nabu.science/paper/10.3389%2Ffimmu.2026.1750735

## Key claims

1. These findings in patients with HAE in China are consistent with the profile of lanadelumab established in patients from other regions, supporting its use as first-line long-term prophylaxis.
   - Support: Tentative
   - Type: Primary finding
   - Basis: first-line positioning outruns the selected, uncontrolled 20-patient design despite consistency with established external evidence
   - Location: Abstract, Conclusion
2. Mean ± SD monthly rate of investigator-confirmed attacks decreased by 99.1% during days 0-182 versus run-in
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported pre/post reduction, though attack-enriched eligibility and no concurrent control limit attribution
   - Location: Abstract, Results; Results, Efficacy
3. No treatment-emergent adverse events (TEAEs) were fatal, led to treatment discontinuation, or were of special interest
   - Support: Supported
   - Type: Secondary
   - Basis: directly observed safety outcomes in the completed 20-patient cohort, with limited precision for uncommon events
   - Location: Abstract, Results; Results, Safety and Tolerability
4. Lanadelumab pharmacokinetics, pharmacodynamics, and immunogenicity in Chinese patients were consistent with other patient populations
   - Support: Supported
   - Type: Secondary
   - Basis: measured profiles align descriptively with historical populations, but the comparison is based on only 20 patients
   - Location: Abstract, Results; Discussion, Pharmacokinetics and Pharmacodynamics

## Strengths

- **Fills a documented Chinese evidence gap** The study prospectively evaluates multiple dimensions of lanadelumab’s profile in Chinese patients, where the Introduction identifies prior evidence as limited mainly to small reports and a recent multicentre observational study.
  - Dimension: contribution
  - Location: Introduction, final paragraph; Discussion, paragraph 1
- **Multiple measures corroborate attack outcomes** Investigator-confirmed diary outcomes were accompanied by similar patient-reported sensitivity results and sustained suppression of the pharmacodynamic marker cHMWK. These measures support the direction of the observed treatment-period findings despite the uncontrolled design.
  - Dimension: methodological rigour
  - Location: Results, Efficacy; Supplementary Table 2; Results, Pharmacodynamics and Pharmacokinetics
- **Substantive comparison with prior evidence** The Discussion compares attack reductions and attack-free proportions with HELP, the Japanese phase 3 study, international real-world studies, and Chinese cohorts, including studies reporting smaller effects.
  - Dimension: positioning
  - Location: Discussion, efficacy-comparison paragraphs

## Limitations

- **Selected uncontrolled comparison limits attribution** Eligibility required attacks during a short run-in, after which all patients received open-label treatment. Without a concurrent control or quantitative bias analysis, regression to the mean and period effects remain plausible contributors to the observed reduction.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Treatment; Methods, Patients; Statistical Analysis
- **Small cohort restricts safety inference** Only 20 patients were observed for approximately six months, including two severe treatment-related hepatic events. This sample cannot precisely characterize uncommon adverse events or subgroup differences.
  - Dimension: methodological rigour
  - Location: Results, Safety and Tolerability; Discussion, safety paragraphs and limitations paragraph
- **First-line conclusion exceeds local design** The conclusion states that the findings support first-line prophylaxis, although the study provides uncontrolled local corroboration rather than independent comparative evidence for treatment positioning.
  - Dimension: reporting
  - Location: Abstract, Conclusion; Discussion, final paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Clean. Participant flow, efficacy totals, exposure, and adverse-event descriptions are internally consistent, including the distinction between severe and serious events. The registration and study-start dates are themselves reported consistently, so their ordering is treated under research conduct rather than internal coherence.
- **Research conduct:** Noted. Ethics approvals and informed consent are declared, but the reported study start preceded the stated registration date by approximately three weeks. No conflict-of-interest declaration appears in the supplied article text, while a conditional individual-participant-data availability process is provided.
- **Reference integrity:** Noted. 35 of 35 checkable references verified
  - 38 references in manuscript
  - 3 are books, websites or datasets — counted, but not index-checkable
  - the reference list may be incompletely parsed; counts are indicative
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17